BioPharmSignal logoBioPharmSignal

Biotech News

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences (HRMY)Harmony BiosciencesCompany update

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

Related news

HRMYHarmony Biosciences2026-05-27 12:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

ECORelectroCore2026-06-17 12:00 EST

electroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference

TNXPTonix Pharmaceuticals2026-08-05 11:00 EST

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences

NBIXNeurocrine Biosciences2026-07-21 20:05 EST

Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer

NBIXNeurocrine Biosciences2026-07-09 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-06-04 20:01 EST

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

ALKSAlkermes plc2026-06-03 20:05 EST

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

ANNXAnnexon, Inc.2026-05-27 12:00 EST

Annexon to Participate in Upcoming June Investor Conferences

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

View all latest news

Harmony Biosciences

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the...

Recent company news

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

HRMYHarmony Biosciences2026-08-04 11:30 EST

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

HRMYHarmony Biosciences2026-07-16 12:30 EST

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

HRMYHarmony Biosciences2026-06-11 12:05 EST

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Stock data

Close
38.75 USD
Market cap
1.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States